Human Developmental Biology of Granulocyte Colony-Stimulating Factor

Calhoun, Darlene A; Christensen, Robert D.

doi:10.1016/s0095-5108(05)70039-7

Cited by 34 publications

(17 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, certain malignant cells constitutively secrete high amounts of G-CSF. [19][20][21][22] Colorectal cancer, squamous cell carcinoma, melanoma, ovarian carcinoma, meningioma, and glioma cells have been shown to constitutively express either G-CSF or its receptor. [23][24][25][26][27][28] In the current study, we demonstrate for what we believe to be the first time that Ewing tumor cell lines and patient samples express high levels of both G-CSF and G-CSFR.…”

mentioning

confidence: 99%

Expression of granulocyte‐colony‐stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens

Morales-Arias

Meyers

Bolontrade

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. Ewing sarcoma (ES) is a highly vascular malignancy. It has been demonstrated that both angiogenesis and vasculogenesis contribute to the growth of ES tumors. Granulocyte‐colony‐stimulating factor (G‐CSF), a cytokine known to stimulate bone marrow (BM) stem cell production and angiogenesis, is routinely administered to ES patients after chemotherapy. Whether ES cells and patient tumor samples express G‐CSF and its receptor (G‐CSFR) and whether treatment with this factor enhances tumor growth was examined. METHODS. Human ES cell lines were analyzed for expression of G‐CSF and G‐CSFR in vitro and in vivo. Sixty‐eight paraffin‐embedded and 15 frozen tumor specimens from patients with ES were also evaluated for the presence of G‐CSF and G‐CSFR. The in vivo effect of G‐CSF on angiogenesis and BM cell migration was determined. Using a TC/7‐1 human ES mouse model, the effect of G‐CSF administration on ES tumors was investigated. RESULTS. G‐CSF and G‐CSFR protein and RNA expression was identified in all ES cell lines and patient samples analyzed. In addition, G‐CSF was found to stimulate angiogenesis and BM cell migration in vivo. Tumor growth was found to be significantly increased in mice treated with G‐CSF. The average tumor volume for the group treated with G‐CSF was 1218 mm3 compared with 577 mm3 for the control group (P = .006). CONCLUSIONS. The findings that ES cells and patient tumors expressed both G‐CSF and its receptor in vitro and in vivo and that the administration of G‐CSF promoted tumor growth in vivo suggest that the potential consequences of G‐CSF administration should be investigated further. Cancer 2007. © 2007 American Cancer Society.

show abstract

mentioning

confidence: 99%

Expression of granulocyte‐colony‐stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens

Morales-Arias

Meyers

Bolontrade

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…However, the exact mechanisms of action and interaction of various cytokines are not clearly defined. Granulocyte colony-stimulating factor is an 18.8-kd glycoprotein that participates in the regulation of neutrophil production after binding with its specific receptor (G-CSFRs) by supporting their clonal proliferation and differentiation [22,23]. In addition to its effects on bone marrow and bone marrow-derived cells, it has many diverse effects including those on the GI tract [24].…”

Section: Discussionmentioning

confidence: 99%

Enteral granulocyte colony-stimulating factor for the treatment of mild (stage I) necrotizing enterocolitis: a placebo-controlled pilot study

Canpolat

Yurdakök

Korkmaz

et al. 2006

Journal of Pediatric Surgery

View full text Add to dashboard Cite

“…We concluded that this infiltration was an effect of G-CSF on submucosal intestinal tissue. Granulocyte colony stimulating factor (G-CSF) is an 18.8-kDa glycoprotein that participates in the regulation of neutrophil production after binding with its specific receptor (G-CSF-Rs) by inhibiting apoptosis of granulocytic progenitors and by supporting their clonal proliferation and differentiation [19,20]. In addition to its presence on neutrophils and their progenitors, functional G-CSF-Rs are expressed on a variety of nonhematopoietic cells, including enterocytes of the fetus and neonate [10].…”

Section: Discussionmentioning

confidence: 99%

Protective effects of recombinant human granulocyte colony stimulating factor in a rat model of necrotizing enterocolitis

et al. 2006

View full text Add to dashboard Cite

The role of cytokines and growth factors in the pathophysiology of neonatal necrotizing enterocolitis (NEC) is not defined clearly yet. The aim of this study was to determine the effects of recombinant human granulocyte colony stimulating factor (G-CSF) on intestinal cells in hypoxia-induced experimental NEC in rats. The study was experimented on Sprague Dawley rat pups. Group 1 (untreated, n = 7) rats were subjected to hypoxia-reoxygenation (H/O) and then were returned to standard conditions. Group 2 (G-CSF treated, n = 7) rats were subjected to H/O, and then were treated with G-CSF (100 microg/kg enterally) for 5 days. Group 3 was served as nonhypoxic controls. All animals were killed on day five, and histological examination was performed on intestinal samples. There were no histopathological changes in the control group. The histological findings in untreated rats were similar to those seen in neonatal NEC, with destruction of villi and crypts with extension to the muscularis layer. Intestinal damage was mild in group 2 and these histological changes were better than group 1, and worse than group 3. The mean of histologic grade of group 1 was 2.4 (range 2-3), and in the group 2, it was 1.2 (range 0-2). A difference was found when two groups were compared with each other (P < 0.05). In an experimental model of NEC, G-CSF could have a protective effect on intestinal damage.

show abstract

Human Developmental Biology of Granulocyte Colony-Stimulating Factor

Cited by 34 publications

References 104 publications

Expression of granulocyte‐colony‐stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens

Expression of granulocyte‐colony‐stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens

Enteral granulocyte colony-stimulating factor for the treatment of mild (stage I) necrotizing enterocolitis: a placebo-controlled pilot study

Protective effects of recombinant human granulocyte colony stimulating factor in a rat model of necrotizing enterocolitis

Contact Info

Product

Resources

About